IMPACT BIOMEDICAL INC (IBO)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$4.06-0.98%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · IBO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
“Effectiveness of the Form F-4 marks an important milestone as we advance toward completing our business combination with Zoar,” said Frank D.
Stated in 1 of 1 supplied quarters. Management reported: “Completion of the Business Combination remains subject to approval by Impact’s stockholders, approval for listing PubCo’s ordinary shares on NYSE American, and the satisfaction or waiver, as applicable, of the other closing conditions set forth in the Merger and Share Exchange Agreement.” “There can be no assurance that the Business Combination will be completed on any particular timetable or at all.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
““Effectiveness of the Form F-4 marks an important milestone as we advance toward completing our business combination with Zoar,” said Frank D.”
The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business combination transaction and its continued-listing objectives.
Stated in a supplied disclosure. Management reported: “The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.”
Upon closing, the Business Combination is expected to result in a pharmaceutical company focused on the development and supply of active pharmaceutical ingredients and intermediates for special thera…
Stated in 1 of 1 supplied quarters. Management reported: “Upon closing, the Business Combination is expected to result in a pharmaceutical company focused on the development and supply of active pharmaceutical ingredients and intermediates for special therapeutic treatment areas.”
“Upon closing, the Business Combination is expected to result in a pharmaceutical company focused on the development and supply of active pharmaceutical ingredients and intermediates for special thera…”
Over the trailing year it converted 0.40x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.